Skip to content
DraconiticResearch
Search Sources API
190,335 studies31 sourcesUpdated 26 min ago
Peer-reviewedCC BY 4.0Frontiers in Microbiology

Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome

  • Chunxing Li1
  • XiaoJing Li2
  • Jiaxin Li3
  • Yichao Shi4
  • Lichaoyue Sun1
  • Qin Yang3
  • Zhao Ren1
4 affiliations
  1. 1Department of Pharmacy, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
  2. 2Department of Endocrinology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
  3. 3Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
  4. 4Department of Gastroenterology, Aerospace Central Hospital, Peking University Aerospace School of Clinical Medicine
Read full textPDFDOICite

Abstract

Background: Published meta-analyses present inconsistent findings regarding the effects of probiotics on metabolic syndrome (MetS), with most lacking in-depth mechanistic exploration.

Objective: To systematically assess the efficacy of probiotic/synbiotic interventions for MetS across preclinical and clinical settings, and to explore underlying mechanisms by quantifying inflammatory and metabolic biomarkers.

Methods: We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, CNKI, and Wanfang Data from inception to June 10, 2025. Both animal and clinical studies were included. For outcomes reported in different units, all values were standardized to a single common unit prior to pooling. Meta-analyses were performed using Stata 15.0 to calculate pooled mean differences (MD) and 95% confidence intervals (CIs). Sensitivity and subgroup analyses were used to assess result stability and heterogeneity.

Results: This meta-analysis of 35 studies (12 clinical trials with 696 MetS patients and 23 animal studies) demonstrated significant metabolic improvements with probiotic/synbiotic interventions. In animal models, these interventions can significantly improve body weight (BW) (MD = –13.27 g, 95%CI: –18.66,–7.88), glucose metabolism (fasting plasma glucose (FPG), MD = −41.05 mg/dL, 95%CI: −46.50, −35.60; HbA1c, MD = –1.17%, 95%CI: −1.50, −0.84), lipid metabolism (TG, MD = –51.38 mg/dL, 95%CI: −71.46, −31.30; TC, MD = –36.66 mg/dL, 95%CI: −50.10, −23.22), inflammatory and metabolic targets (IL-6, MD = –15.07 pg./mL, 95%CI: −18.23, −11.91; Leptin, MD = –20.95 ng/mL, 95%CI: −39.79, −2.11; FFA, MD = –130.36 μmol/L, 95%CI: −191.52, −69.21), as well as liver function indicators in animal models of MetS. In patients, changes in FPG were non-significant (MD = –8.76 mg/dL, 95%CI:–18.29,0.77), whereas significant improvements were observed for BW (MD = –1.06 kg, 95%CI:–1.70,-0.42), waist circumference (MD = –2.12 cm, 95%CI:–3.70,–0.55), and lipid profiles: TG (MD = -20.51 mg/dL, 95%CI:–27.69,–13.34), TC (MD = -12.09 mg/dL, 95%CI:–16.15,–8.04), LDL-C (MD = –10.56 mg/dL, 95%CI:–14.96,–6.17), and HDL-C (MD = 1.97 mg/dL, 95%CI:0.55,3.39). Sensitivity analyses confirmed result stability, with low risk of publication bias.

Conclusion: Probiotic and synbiotic supplementation effectively improves body composition and lipid metabolism in MetS patients and animal models, and improves glucose metabolism in animals. In MetS patients, supplementation reduces HbA1c without altering FPG. These interventions produce favorable changes in adipokines, inflammatory cytokines and metabolic stress markers. Further high-quality, long-term RCTs are required to validate these effects and optimize intervention strategies.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifiers CRD420261373917 and CRD420261374049.

Related

  1. Effects of probiotic or synbiotic supplementation on glycolipid metabolism in patients with coronary heart disease: a systematic review and meta-analysis
    Yanan Bai, Yunfeng Yu, Xiangning Huang +3
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMicrobiologyCrossrefDOAJ
  2. Prebiotic, probiotic, and chlorophyllin interventions differentially attenuate melphalan-induced intestinal injury and modulate gut metabolite profiles
    Archana Kumari Redhu, Saithang Puia, Nitesh Chavan +7
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0MicrobiologyCrossref
  3. Pharmacological and Therapeutic Potential of Garlic ( Allium sativum ): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence
    Gudisa Bereda
    ChemistryOpenPeer-reviewedCC BY 4.0Full textPlant biologyCrossrefPMC
  4. Probiotic and postbiotic treatment improves coral health and promotes specific metabolic and microbiome changes in situ during a heatwave
    Érika P. Santoro, Inês Raimundo, Laura Beenham +11
    Cell ReportsPeer-reviewedCC BY-NC-NDFull text6 citedEcologyOpenAlex
  5. The Therapeutic Potential of Berry-Derived and Berry-Based Interventions in Inflammatory Bowel Disease: A Comprehensive Systematic Review of Preclinical and Clinical Evidence
    Lucia Carmela Passacatini, Rosamaria Caminiti, Valeria Mazza +14
    NutrientsPeer-reviewedCC BYFull textGenetics & genomicsEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{li2026integrating,
  title = {{Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome}},
  author = {Chunxing Li and XiaoJing Li and Jiaxin Li and Yichao Shi and Lichaoyue Sun and Qin Yang and Zhao Ren},
  journal = {Frontiers in Microbiology},
  year = {2026},
  month = oct,
  doi = {10.3389/fmicb.2026.1995383},
  url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1995383/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome
AU  - Chunxing Li
AU  - XiaoJing Li
AU  - Jiaxin Li
AU  - Yichao Shi
AU  - Lichaoyue Sun
AU  - Qin Yang
AU  - Zhao Ren
PY  - 2026
DA  - 2026/10/15
JO  - Frontiers in Microbiology
DO  - 10.3389/fmicb.2026.1995383
UR  - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1995383/full
AB  - Background: Published meta-analyses present inconsistent findings regarding the effects of probiotics on metabolic syndrome (MetS), with most lacking in-depth mechanistic exploration.  Objective: To systematically assess the efficacy of probiotic/synbiotic interventions for MetS across preclinical and clinical settings, and to explore underlying mechanisms by quantifying inflammatory and metabolic biomarkers.  Methods: We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, CNKI, and Wanfang Data from inception to June 10, 2025. Both animal and clinical studies were included. For outcomes reported in different units, all values were standardized to a single common unit prior to pooling. Meta-analyses were performed using Stata 15.0 to calculate pooled mean differences (MD) and 95% confidence intervals (CIs). Sensitivity and subgroup analyses were used to assess result stability and heterogeneity.  Results: This meta-analysis of 35 studies (12 clinical trials with 696 MetS patients and 23 animal studies) demonstrated significant metabolic improvements with probiotic/synbiotic interventions. In animal models, these interventions can significantly improve body weight (BW) (MD = –13.27 g, 95%CI: –18.66,–7.88), glucose metabolism (fasting plasma glucose (FPG), MD = −41.05 mg/dL, 95%CI: −46.50, −35.60; HbA1c, MD = –1.17%, 95%CI: −1.50, −0.84), lipid metabolism (TG, MD = –51.38 mg/dL, 95%CI: −71.46, −31.30; TC, MD = –36.66 mg/dL, 95%CI: −50.10, −23.22), inflammatory and metabolic targets (IL-6, MD = –15.07 pg./mL, 95%CI: −18.23, −11.91; Leptin, MD = –20.95 ng/mL, 95%CI: −39.79, −2.11; FFA, MD = –130.36 μmol/L, 95%CI: −191.52, −69.21), as well as liver function indicators in animal models of MetS. In patients, changes in FPG were non-significant (MD = –8.76 mg/dL, 95%CI:–18.29,0.77), whereas significant improvements were observed for BW (MD = –1.06 kg, 95%CI:–1.70,-0.42), waist circumference (MD = –2.12 cm, 95%CI:–3.70,–0.55), and lipid profiles: TG (MD = -20.51 mg/dL, 95%CI:–27.69,–13.34), TC (MD = -12.09 mg/dL, 95%CI:–16.15,–8.04), LDL-C (MD = –10.56 mg/dL, 95%CI:–14.96,–6.17), and HDL-C (MD = 1.97 mg/dL, 95%CI:0.55,3.39). Sensitivity analyses confirmed result stability, with low risk of publication bias.  Conclusion: Probiotic and synbiotic supplementation effectively improves body composition and lipid metabolism in MetS patients and animal models, and improves glucose metabolism in animals. In MetS patients, supplementation reduces HbA1c without altering FPG. These interventions produce favorable changes in adipokines, inflammatory cytokines and metabolic stress markers. Further high-quality, long-term RCTs are required to validate these effects and optimize intervention strategies.  Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifiers CRD420261373917 and CRD420261374049.
SN  - 1664-302X
ER  -